@inproceedings{f37758d541a84377a28049dbf53f6aa7,
title = "Quantitative assessment of the relationship between myocardial lesion formation detected by delayed contrast-enhanced magnetic resonance imaging and proton beam planning dose for treatment of ventricular tachycardia",
abstract = "Proton beam therapy has recently been proposed as a noninvasive approach for treating ventricular tachycardia (VT), where target regions are identified in the myocardium and treated using external beam therapy. Effective treatment requires that lesions develop at target sites of myocardial tissue in order to stop arrhythmic pathways. Precise characterization of the dose required for lesion creation is required for determining appropriate dose levels in future clinical treatment of VT patients. In this work, we use a deformable registration algorithm to align proton beam delivery isodose lines planned from baseline computed-tomography scans to follow-up delayed contrast-enhanced magnetic resonance imaging scans in three swine studies. The relationship between myocardial lesion formation and delivered dose from external proton beam ablation therapy is then quantitatively assessed. The current study demonstrates that myocardial tissue receiving a dose of 20Gy or higher tends to develop into lesion, while tissue exposed to less than 10Gy of dose tends to remain healthy. Overall, this study quantifies the relationship between external proton beam therapy dose and myocardial lesion formation which is important for determining dose levels in future clinical treatment of VT patients.",
author = "Rettmann, {M. E.} and A. Suzuki and Deisher, {A. J.} and S. Hohmann and H. Konishi and S. Wang and Kruse, {J. J.} and Newman, {L. K.} and Parker, {K. D.} and Herman, {M. G.} and Packer, {D. L.}",
note = "Funding Information: D.L. Packer receives research funding from the American Heart Association Foundation, Biosense Webster, Boston Scientific/EPT, CardioInsight, CardioFocus, Endosense, Hansen Medical, Medtronic CryoCth LP, NIH, St. Jude Medical, Siemens and Thermedical. Royalties from Wiley & Sons and St. Jude Medical. Dr. Packer and Mayo Clinic jointly have equity in a privately held company, External Beam Ablation Medical Devices. Mayo Clinic and D.L. Packer have a financial interest in mapping technology. In accordance with the Bayh-Dole Act, this technology has been licensed to St. Jude Medical, and Mayo Clinic and D.L. Packer have received annual royalties greater than $10,000, the federal threshold for significant financial interest. Funding Information: This work is funded by a Mayo Clinic CTSA grant UL1TR000135. S.H. is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) project no. 380200397. Funding Information: This work is funded by a Mayo Clinic CTSA grant UL1TR000135. S.H. is funded by the Deutsche Forschungs-gemeinschaft (DFG, German Research Foundation) project no. 380200397. Publisher Copyright: {\textcopyright} 2019 SPIE.; Medical Imaging 2019: Image-Guided Procedures, Robotic Interventions, and Modeling ; Conference date: 17-02-2019 Through 19-02-2019",
year = "2019",
doi = "10.1117/12.2513920",
language = "English (US)",
series = "Progress in Biomedical Optics and Imaging - Proceedings of SPIE",
publisher = "SPIE",
editor = "Baowei Fei and Linte, {Cristian A.}",
booktitle = "Medical Imaging 2019",
}